Black patients who receive docetaxel for breast cancer experience less peripheral neuropathy than those who receive paclitaxel

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

UPMC Hillman Cancer Center at Zabok General Hospital in Croatia is expanding access to the most advanced radiosurgery services for people across the country with the introduction of the Varian TrueBeam stereotactic body radiation therapy and stereotactic radiosurgery system. The new system delivers radiosurgery treatment with pinpoint accuracy and image-guided precision in a shorter amount of time than current conventional treatments.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login